Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing

被引：149

作者：

Martin, M. A. ^{[1
]}

Klein, T. E. ^{[2
]}

Dong, B. J. ^{[3
]}

Pirmohamed, M. ^{[4
]}

Haas, D. W. ^{[5
,6
,7
]}

Kroetz, D. L. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA

[2] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[3] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA

[4] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England

[5] Vanderbilt Univ, Dept Med, Nashville, TN USA

[6] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA

[7] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 91卷 / 04期

基金：

美国国家卫生研究院;

关键词：

HUMAN-LEUKOCYTE ANTIGEN-B-ASTERISK-5701; HYPERSENSITIVITY REACTIONS; DRUG HYPERSENSITIVITY; MYOCARDIAL-INFARCTION; HLA-B-ASTERISK-5701; THERAPY; ASSOCIATION; HIV-1; MARKER; B-ASTERISK-5701;

D O I：

10.1038/clpt.2011.355

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B(star)57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects similar to 6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.

引用

页码：734 / 738

页数：5

共 40 条

[1] Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America [J].

Aberg, Judith A. ;

Kaplan, Jonathan E. ;

Libman, Howard ;

Emmanuel, Patricia ;

Anderson, Jean R. ;

Stone, Valerie E. ;

Oleske, James M. ;

Currier, Judith S. ;

Gallant, Joel E. .

CLINICAL INFECTIOUS DISEASES, 2009, 49 (05) :651-681

[2] Delayed drug hypersensitivity: models of T-cell stimulation [J].

Adam, Jacqueline ;

Pichler, Werner J. ;

Yerly, Daniel .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (05) :701-707

[3]

Almeida CAM, 2008, ANTIVIR THER, V13, P281

[4]

[Anonymous], GUID US ANT AG HIV 1

[5]

Becquemont L, 2011, PHARMACOGENOMICS, V12, P113, DOI [10.2217/pgs.10.147, 10.2217/PGS.10.147]

[6] Abacavir Use and Risk of Acute Myocardial Infarction and Cerebrovascular Events in the Highly Active Antiretroviral Therapy Era [J].

Bedimo, Roger J. ;

Westfall, Andrew O. ;

Drechsler, Henning ;

Vidiella, Gabriela ;

Tebas, Pablo .

CLINICAL INFECTIOUS DISEASES, 2011, 53 (01) :84-91

[7] Human leukocyte antigens and drug hypersensitivity [J].

Chung, Wen-Hung ;

Hung, Shuen-Lu ;

Chen, Yuan-Tsong .

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 7 (04) :317-323

[8] A marker for Stevens-Johnson syndrome [J].

Chung, WH ;

Hung, SI ;

Hong, HS ;

Hsih, MS ;

Yang, LC ;

Ho, HC ;

Wu, JY ;

Chen, YT .

NATURE, 2004, 428 (6982) :486-486

[9] Mechanisms of MHC class I-restricted antigen processing and cross-presentation [J].

Cresswell, P ;

Ackerman, AL ;

Giodini, A ;

Peaper, DR ;

Wearsch, PA .

IMMUNOLOGICAL REVIEWS, 2005, 207 :145-157

[10] HLA-B☆5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin [J].

Daly, Ann K. ;

Donaldson, Peter T. ;

Bhatnagar, Pallav ;

Shen, Yufeng ;

Pe'er, Itsik ;

Floratos, Aris ;

Daly, Mark J. ;

Goldstein, David B. ;

John, Sally ;

Nelson, Matthew R. ;

Graham, Julia ;

Park, B. Kevin ;

Dillon, John F. ;

Bernal, William ;

Cordell, Heather J. ;

Pirmohamed, Munir ;

Aithal, Guruprasad P. ;

Day, Christopher P. .

NATURE GENETICS, 2009, 41 (07) :816-U71

← 1 2 3 4 →